Patents by Inventor Theodorus Hendrikus Jacobus Kwaks
Theodorus Hendrikus Jacobus Kwaks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160002318Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.Type: ApplicationFiled: September 17, 2015Publication date: January 7, 2016Inventors: Ronald Vogels, Theodorus Hendrikus Jacobus Kwaks
-
Patent number: 9228004Abstract: Described is a DNA molecule comprising an open reading frame sequence encoding a selectable marker polypeptide, wherein the DNA molecule in the coding strand comprises a translation start sequence for the selectable marker polypeptide having a GTG or TTG start codon, and wherein the ORF sequence that encodes the selectable marker protein has been mutated to replace at least half of its CpG dinucleotides as compared to the native ORF sequence that encodes the selectable marker protein. Further provided are such DNA molecules wherein the ORF sequence that encodes a selectable marker polypeptide is part of a multicistronic transcription unit that further comprises an open reading frame sequence encoding a polypeptide of interest. Also described are methods for obtaining host cells expressing a polypeptide of interest, wherein the host cells comprise the DNA molecules described herein.Type: GrantFiled: November 15, 2013Date of Patent: January 5, 2016Assignee: ChromaGenics B.V.Inventors: Arie Pieter Otte, Henricus J.M. van Blokland, Theodorus Hendrikus Jacobus Kwaks, Richard George Antonius Bernardus Sewalt
-
Patent number: 9200064Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.Type: GrantFiled: October 13, 2014Date of Patent: December 1, 2015Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Theodorus Hendrikus Jacobus Kwaks
-
Patent number: 8961978Abstract: The present disclosure relates to binding molecules, such as human monoclonal antibodies, that bind to an epitope in the stem region of hemagglutinin of influenza A viruses of phylogenetic group 1 and group 2, as well as influenza B viruses, and have a broad neutralizing activity against such influenza viruses. The disclosure provides nucleic acid molecules encoding the binding molecules, their sequences and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of influenza A viruses of phylogenetic groups 1 and 2, as well as influenza B viruses.Type: GrantFiled: July 12, 2012Date of Patent: February 24, 2015Assignee: Crucell Holland B.V.Inventors: Theodorus Hendrikus Jacobus Kwaks, David Adrianus Theodorus Maria Zuijdgeest, Ronald Vogels, Robert Heinz Edward Friesen
-
Publication number: 20150037345Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.Type: ApplicationFiled: October 13, 2014Publication date: February 5, 2015Inventors: Ronald Vogels, Theodorus Hendrikus Jacobus Kwaks
-
Publication number: 20140186890Abstract: Provided is a DNA molecule comprising a multicistronic transcription unit coding for i) a selectable marker polypeptide functional in a eukaryotic host cell, and for ii) a polypeptide of interest, the polypeptide of interest having a translation initiation sequence separate from that of the selectable marker polypeptide, wherein the coding sequence for the polypeptide of interest is downstream from the coding sequence for the selectable marker in the multicistronic transcription unit, and the nucleic acid sequence coding for the selectable marker polypeptide comprises a mutation that decreases the translation efficiency of the selectable marker in a eukaryotic host cell. Also provided are methods for obtaining host cells expressing a polypeptide of interest, the host cells comprising the described DNA molecules. Further provided is the production of polypeptides of interest, comprising culturing host cells comprising the DNA molecules hereof.Type: ApplicationFiled: January 27, 2014Publication date: July 3, 2014Applicant: CHROMAGENICS B.V.Inventors: Arie Pieter OTTE, Henricus J.M. VAN BLOKLAND, Theodorus Hendrikus Jacobus KWAKS, Richard George Antonius Bernardus SEWALT
-
Publication number: 20140120113Abstract: The present disclosure relates to binding molecules, such as human monoclonal antibodies, that bind to an epitope in the stem region of hemagglutinin of influenza A viruses of phylogenetic group 1 and group 2, as well as influenza B viruses, and have a broad neutralizing activity against such influenza viruses. The disclosure provides nucleic acid molecules encoding the binding molecules, their sequences and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of influenza A viruses of phylogenetic groups 1 and 2, as well as influenza B viruses.Type: ApplicationFiled: July 12, 2012Publication date: May 1, 2014Applicant: Crucell Holland B.V.Inventors: Theodorus Hendrikus Jacobus Kwaks, David Adrianus Theodorus Maria Zuijdgeest, Ronald Vogels, Robert Heinz Edward Friesen
-
Publication number: 20140106401Abstract: Described is a DNA molecule comprising an open reading frame sequence encoding a selectable marker polypeptide, wherein the DNA molecule in the coding strand comprises a translation start sequence for the selectable marker polypeptide having a GTG or TTG start codon, and wherein the ORF sequence that encodes the selectable marker protein has been mutated to replace at least half of its CpG dinucleotides as compared to the native ORF sequence that encodes the selectable marker protein. Further provided are such DNA molecules wherein the ORF sequence that encodes a selectable marker polypeptide is part of a multicistronic transcription unit that further comprises an open reading frame sequence encoding a polypeptide of interest. Also described are methods for obtaining host cells expressing a polypeptide of interest, wherein the host cells comprise the DNA molecules described herein.Type: ApplicationFiled: November 15, 2013Publication date: April 17, 2014Applicant: ChromaGenics B.V.Inventors: Arie Pieter Otte, Henricus J.M. van Blokland, Theodorus Hendrikus Jacobus Kwaks, Richard George Antonius Bernardus Sewalt
-
Patent number: 8470327Abstract: Binding molecules, such as human monoclonal antibodies, that bind to influenza virus comprising HA of the H3 subtype, such as H3N2, and have a broad neutralizing activity against such influenza virus. Provided are nucleic acid molecules encoding the antibodies, their sequences and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis and/or treatment of an influenza virus H3N2 infection. The antibodies may provide cross-subtype protection, such that infections with H3, H7, and/or H10-based influenza subtypes can be prevented and/or treated.Type: GrantFiled: May 6, 2010Date of Patent: June 25, 2013Assignee: Crucell Holland B.V.Inventors: Mark Throsby, Robert Heinz Edward Friesen, Theodorus Hendrikus Jacobus Kwaks, Mandy Antonia Catharina Jongeneelen
-
Patent number: 8263393Abstract: Described are means and methods for providing a cell with a protein expression unit, the method comprising providing a nucleic acid sequence comprising the unit with a nucleic acid sequence encoding a binding site for a member of a chromatin modification system for rendering chromatin more accessible for transcription (opener), wherein the opener is present in the cell. Preferred openers comprise histone modification proteins, chromatin remodeling proteins and trithorax group proteins or equivalents. The cells thus generated and nucleic acid sequences encoding such openers are provided. Openers are preferred in the context of STAR and TRAP sequences.Type: GrantFiled: June 20, 2005Date of Patent: September 11, 2012Assignee: Chromagenics B.V.Inventors: Arie Pieter Otte, Theodorus Hendrikus Jacobus Kwaks, Richard George Antonius Bernardus Sewalt
-
Publication number: 20120039898Abstract: Binding molecules, such as human monoclonal antibodies, that bind to influenza virus comprising HA of the H3 subtype, such as H3N2, and have a broad neutralizing activity against such influenza virus. Provided are nucleic acid molecules encoding the antibodies, their sequences and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis and/or treatment of an influenza virus H3N2 infection. The antibodies may provide cross-subtype protection, such that infections with H3, H7, and/or H10-based influenza subtypes can be prevented and/or treated.Type: ApplicationFiled: May 6, 2010Publication date: February 16, 2012Inventors: Mark Throsby, Robert Heinz Edward Friesen, Theodorus Hendrikus Jacobus Kwaks, Mandy Antonia Catharina Jongeneelen
-
Publication number: 20110300580Abstract: Described is a DNA molecule comprising an open reading frame sequence that encodes a selectable marker polypeptide, wherein the DNA molecule in the coding strand comprises a translation start sequence for the selectable marker polypeptide having a GTG start codon or a TTG start codon, and wherein the ORF sequence that encodes the selectable marker protein has been mutated to replace at least half of its CpG dinucleotides as compared to the native ORF sequence that encodes the selectable marker protein. Further provided are such DNA molecules wherein the ORF sequence that encodes a selectable marker polypeptide is part of a multicistronic transcription unit that further comprises an open reading frame sequence encoding a polypeptide of interest. Also described are methods for obtaining host cells expressing a polypeptide of interest, wherein the host cells comprise the DNA molecules described herein.Type: ApplicationFiled: July 18, 2011Publication date: December 8, 2011Inventors: Arie Pieter Otte, Henricus Johannes Maria Van Blokland, Theodorus Hendrikus Jacobus Kwaks, Richard George Antonius Bernardus Sewalt
-
Patent number: 7968700Abstract: The invention provides recombinant DNA molecules comprising novel expression augmenting DNA fragments and an expression cassette, said expression cassette comprising a heterologous promoter linked to a nucleic acid of interest. The invention further provides uses of the novel expression augmenting DNA fragments. The invention further provides methods for obtaining novel expression augmenting DNA fragments.Type: GrantFiled: March 20, 2007Date of Patent: June 28, 2011Assignee: Chromagenics B.V.Inventors: Arie Pieter Otte, Henricus Johannes Maria Van Blokland, Theodorus Hendrikus Jacobus Kwaks, Richard George Antonius Bernardus Sewalt
-
Patent number: 7825232Abstract: The invention provides a novel anti-repressor element, which is useful for improving expression of nucleic acid in host cells. Methods using the novel anti-repressor element for producing a protein of interest are also provided. The invention also provides new configurations of expression cassettes comprising anti-repressor elements.Type: GrantFiled: July 7, 2005Date of Patent: November 2, 2010Assignee: Chromagenics B.V.Inventors: Arie Pieter Otte, Theodorus Hendrikus Jacobus Kwaks, Richard George Antonius Bernardus Sewalt, Henricus Johannes Maria Van Blokland
-
Publication number: 20100190207Abstract: The invention provides recombinant DNA molecules comprising novel expression augmenting DNA fragments and an expression cassette, said expression cassette comprising a heterologous promoter linked to a nucleic acid of interest. The invention further provides uses of the novel expression augmenting DNA fragments. The invention further provides methods for obtaining novel expression augmenting DNA fragments.Type: ApplicationFiled: March 20, 2007Publication date: July 29, 2010Inventors: Arie Pieter Otte, Henricus Johannes Maria Van Blokland, Theodorus Hendrikus Jacobus Kwaks, Richard George Antonius Bernardus Sewalt
-
Publication number: 20100136616Abstract: The invention provides a DNA molecule comprising a multicistronic transcription unit coding for i) a polypeptide of interest, and for ii) a selectable marker polypeptide functional in a eukaryotic host cell, wherein the polypeptide of interest has a translation initiation sequence separate from that of the selectable marker polypeptide, and wherein the coding sequence for the polypeptide of interest is upstream from the coding sequence for the selectable marker polypeptide in said multicistronic transcription unit, and wherein an internal ribosome entry site (IRES) is present downstream from the coding sequence for the polypeptide of interest and upstream from the coding sequence for the selectable marker polypeptide, and wherein the nucleic acid sequence coding for the selectable marker polypeptide in the coding strand comprises a GTG or a TTG startcodon.Type: ApplicationFiled: February 21, 2007Publication date: June 3, 2010Inventors: Arie Pieter Otte, Henricus Johannes Maria Van Blokland, Theodorus Hendrikus Jacobus Kwaks, Richard George Anotius Bernardus Sewalt
-
Publication number: 20090098601Abstract: The invention provides a DNA molecule comprising an open reading frame sequence that encodes a selectable marker polypeptide, wherein said DNA molecule in the coding strand comprises a translation start sequence for the selectable marker polypeptide having a GTG startcodon or a TTG startcodon, and wherein the open reading frame sequence that encodes the selectable marker protein has been mutated to replace at least half of its CpG dinucleotides as compared to the native open reading frame sequence that encodes the selectable marker protein.Type: ApplicationFiled: April 24, 2007Publication date: April 16, 2009Inventors: Arie Pieter Otte, Henricus Johannes Maria Van Blokland, Theodorus Hendrikus Jacobus Kwaks, Richard George Antonius Bernardus Sewalt